Introduction {#sec1_1}
============

Acute liver failure (ALF) is a critical condition that can occasionally lead to death. Liver transplantation is an essential treatment option for ALF. Ho et al. \[[@B1]\] have reported that infectious diseases, alcohol abuse, and malignancy are several risk factors associated with poor prognosis in ALF patients. Clinicians need to pay special attention to the management of these risk factors.

On-line hemodiafiltration (OLHDF) uses a large amount of sterile dialysate as a substitution fluid and helps patients with ALF to achieve restoration of consciousness \[[@B2]\]. One of the advantages of OLHDF is that it removes ammonia, which could cause disturbances of consciousness in ALF patients. Occasionally, central venous catheters and bloodstream infection occur during HDF treatment. OLHDF is one of the most effective artificial liver support devices \[[@B2]\] in the treatment of ALF, and managing OLHDF without infections is preferable. In Japan as well as the USA, organ shortage is one of the problems in the field of liver transplantation \[[@B3]\]. Even patients with ALF should wait for a proper liver donor for deceased donor liver transplantation or living donor liver transplantation.

We report a patient with ALF associated with benzbromarone use who received OLHDF via an arteriovenous fistula to avoid infectious complications, and he was successfully rescued by liver transplantation.

Case Report {#sec1_2}
===========

A 59-year-old Japanese man who had liver dysfunction for over 1 year was referred to the former hospital with fatigue and jaundice. Prior to developing liver dysfunction, he had been diagnosed with hyperuricemia, hypertension, and dyslipidemia. Benzbromarone 50 mg daily, benidipine 4 mg daily, and pravastatin 5 mg daily were all prescribed. He also drank alcohol (∼60 g daily). After he had been diagnosed with liver dysfunction, ursodeoxycholic acid 400 mg daily was prescribed. The laboratory examinations on admission to the former hospital showed the following values: total bilirubin, 8.1 mg/dl; aspartate transaminase (AST), 1,457 IU/l; alanine transaminase (ALT), 1,696 IU/l; prothrombin time (PT), 69%, and PT international normalized ratio (PT-INR), 1.33. Eight days after admission to the former hospital, the laboratory examinations showed the following values: total bilirubin level, 21.6 mg/dl; AST, 340 IU/l; ALT, 529 IU/l; PT, 38%, and PT-INR, 1.82. Although he had received conservative treatment, disorientation, drowsiness, and incontinence appeared 14 days after his prior hospitalization, and he was diagnosed as having ALF with grade 2 hepatic encephalopathy \[[@B3]\].

The patient was transferred to the Chiba University Hospital for treatment of the ALF. On admission, his body height and weight were 1.63 m and 60.2 kg, respectively. On physical examination, deep jaundice, abdominal distension, and leg edema were observed. His liver and spleen were not palpable. Flapping tremor and disorientation were also detected.

The patient\'s laboratory data on this admission are shown in table [1](#T1){ref-type="table"}. The serologic and virologic markers were negative. Autoimmune hepatitis was also ruled out \[[@B4]\]. Based on his medical history, we suspected that the benzbromarone was responsible for his hepatic injury \[[@B5], [@B6]\]. CT imaging demonstrated heterogeneous hypoattentuation and atrophy of the liver with massive ascites (fig. [1](#F1){ref-type="fig"}). The Model for End-Stage Liver Disease (MELD) score of the patient was 24 \[[@B7]\]. He fulfilled a number of the criteria for liver transplantation. He was registered as a potential liver recipient, and we continued medical treatment. Until liver transplantation, intermittent OLHDF was performed to improve the disturbances in his level of consciousness. Surgical construction of an arteriovenous fistula was performed in the right forearm 12 days after admission to our unit. After evaluating the condition of his blood vessels, the fistula was constructed in the right forearm. The deceased donor liver transplantation was successfully performed without any infectious complications 53 days after admission to our unit. The volume of his liver was 730 g, and histology of the liver revealed submassive necrosis in the right lobe and massive necrosis in the left lobe (fig. [2](#F2){ref-type="fig"}). There was no evidence of liver cirrhosis, supporting the diagnosis of ALF rather than acute-on-chronic liver failure \[[@B8]\]. During his hospitalization, no symptoms of infectious complications were observed (fig. [3](#F3){ref-type="fig"}). He remains well 1.5 years following transplantation. The fistula in his right forearm was closed 1 month after the liver transplantation.

Discussion {#sec1_3}
==========

The clinical course of ALF is associated with rapidly progressive multiorgan failure and devastating complications such as encephalopathy and coagulopathy \[[@B4]\]. The present case had hepatic encephalopathy and coagulopathy. On admission to our hospital, this patient had grade 2 hepatic encephalopathy. Hemodiafiltration was essential to maintain the patient\'s level of consciousness \[[@B9]\]. He did not slip into coma.

On the other hand, sepsis is one of the poor prognostic factors for ALF \[[@B1]\]. Fujiwara et al. \[[@B10]\] reported that bacterial bloodstream infection was found in 35% of cases with infectious complications in autoimmune ALF \[[@B10]\]. Infection is also an important prognostic factor for morbidity and mortality in hemodialysis and OLHDF patients with ALF \[[@B11]\]. Vascular access-related infection occurs frequently, and patients with arteriovenous fistulas for hemodialysis are at lower risk of death and infections when compared to patients with catheters \[[@B12]\]. In addition, Moura et al. \[[@B13]\] reported that patients who have arteriovenous fistulas for vascular access have higher health-related quality of life scores when compared to patients using central venous catheters. The patient in this report was initially admitted to the intensive care unit in our hospital. After he received an arteriovenous fistula, he was able to walk and perform rehabilitation training in a general patient room.

Our patient successfully avoided the risk of infectious diseases by having an arteriovenous fistula created in the right forearm for dialysis. His level of consciousness was maintained by intermittent rather than continuous OLHDF, and this might also have been beneficial to avoid other infections. There have been several reports that benzbromarone is occasionally associated with ALF \[[@B14], [@B15]\]. When prescribing benzbromarone, clinicians should pay attention to the possibility of liver dysfunction. There may be no evidence to support this assumption, and not all patients transplanted for ALF who require temporary renal support via a dialysis catheter develop infections.

In conclusion, forming an arteriovenous fistula for dialysis may be a beneficial option in the management of ALF, although the excellent outcome in our patient was most likely related to the excellent care and surgical technique of the transplant team.
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![Contrast-enhanced CT revealed necrotic changes (arrows) and atrophy of the liver with massive ascites (**a**, **b**; \*\*) and bilateral pleural effusions (**b**; \*).](crg-0010-0139-g01){#F1}

![A histological examination was conducted on the explanted liver. The microscopic findings revealed massive hemorrhagic necrosis. \* Central veins of the liver. HE. **a** ×40. **b** ×200.](crg-0010-0139-g02){#F2}

![Chart showing the course of ALT, PT-INR, and total bilirubin from first admission until liver transplantation. Total bilirubin level plateaued with medical treatment until liver transplantation.](crg-0010-0139-g03){#F3}

###### 

Laboratory data on admission to our hospital

  Parameter                    Result        Normal value   Parameter              Result   Normal value
  ---------------------------- ------------- -------------- ---------------------- -------- --------------
  White blood cells, n/μl      17,000        4,000--9,000   HBsAg                  --       --
  Eosinophils, %               0             1.0--5.0       IgM-anti-HBc           --       --
  Red blood cells, n/μl        482 × 10^4^   410--530       HBV DNA                --       --
  Hemoglobin, g/dl             15.7          14.0--17.0     IgM-anti-HA            --       --
  Platelets, n/μl              9.5 × 10^4^   15.0--35.0     anti-HCV               --       --
  PT, %                        32            81--121        HCV RNA                --       --
  PT-INR                       1.65          0.86--1.06     IgA-anti-HEV           --       --
  Total cholesterol, mg/dl     140           125--219       anti-HIV               --       --
  Total protein, g/dl          5.8           6.5--8.2       anti-HTLV-I            --       --
  Albumin, g/dl                2.9           3.9--5.1       IgG, mg/dl             1,312    870--1,700
  AST, IU/l                    68            13--33         IgA, mg/dl             253      110--410
  ALT, IU/l                    256           8--42          IgM, mg/dl             42       35--220
  LDH, IU/l                    399           119--229       HGF, ng/ml             1.58     \<0.4
  ALP, IU/l                    690           115--359       ANA                    --       --
  γ-GTP, IU/l                  138           10--47         ASMA                   --       --
  Total bilirubin, mg/dl       23.6          0.2--1.2       AMA M2                 --       --
  Direct bilirubin, mg/dl      16.8          0--0.2         Ceruloplasmin, μg/dl   102      21--37
  Blood urea nitrogen, mg/dl   16            8--20          AFP, ng/ml             12.5     \<8.0
  Creatinine, mg/dl            0.63          0.61--1.04     Ammonia, μg/dl         81       12--66
  Glucose, mg/dl               214           70--119        TSH, μlU/ml            0.082    0.350--4.940
  CRP, mg/dl                   0.3           0.0--0.2       fT~3~, pg/ml           1.20     1.71--3.71
  ESR, mm/h                    1             2--10          fT~4~, ng/dl           0.98     0.70--1.48

AFP = α-Fetoprotein; ALP = alkaline phosphatase; AMA M2 = anti-mitochondrial antibody M2; ANA = anti-nuclear antibody; anti-HCV = anti-hepatitis C virus antibody; anti-HIV = anti-human immunodeficiency virus antibody; anti-HTLV-I = anti-human T-cell leukemia virus; ASMA = anti-smooth muscle antibody; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; fT~3~ = free triiodothyronine; fT~4~ = free thyroxine; γ-GTP = γ-glutamyltransferase; HBsAg = hepatitis B surface antigen; HBV DNA = hepatitis B virus DNA; HCV RNA = hepatitis C virus RNA; HGF = hepatic growth factor; IgA = immunoglobulin A; IgA-anti-HEV = anti-hepatitis E virus IgA antibody; IgG = immunoglobulin G; IgM = immunoglobulin M; IgM-anti-HA = anti-hepatitis A IgM antibody; IgM-anti-HBc = anti-HBV core IgM antibody; LDH = lactate dehydrogenase; TSH = thyroid-stimulating hormone; -- = negative.
